Physician profile
Maria E Taveras
NPI 1184632127
$2,581.53
in general payments reported to CMS, 2019-2025
21 companies · $45.15 in 2025
The $45.15 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,088 · 2020: $136 · 2021: $15.39 · 2022: $136 · 2023: $66.98 · 2024: $93.97 · 2025: $45.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $478.84 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $382.09 | 2019-2022 | |
| Amgen INC. | $202.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $187.40 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $179.84 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.49 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.21 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $167.72 | 2019 | |
| Pfizer INC. | $143.13 | 2019-2020 | |
| Cook Medical LLC | $92.19 | 2023-2025 | Cook Celect, Rosen, Tornado |
| Lundbeck LLC | $87.20 | 2019 | |
| Akcea Therapeutics, INC. | $52.33 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $51.76 | 2019 | |
| Medtronic, INC. | $49.48 | 2024 | Endurant Iis |
| Novo Nordisk INC | $38.56 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $34.57 | 2019 | |
| Kestra Medical Technology Services, INC. | $28.86 | 2023 | Assure Wcd |
| United Therapeutics Corporation | $13.38 | 2019 | |
| Convatec INC. | $13.28 | 2019 | |
| Scpharmaceuticals INC. | $13.11 | 2024 | |
| Gilead Sciences, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Taveras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.